FDA Panel On Moxduo: Two Opioids Are Not Better Than One
This article was originally published in The Pink Sheet Daily
Executive Summary
Anesthetic and Analgesic Drugs Products Advisory Committee unanimously recommends against approval of QRxPharma’s fixed-dose combination of morphine and oxycodone but says exploratory analyses suggesting a reduced risk of deep oxygen desaturation should be tested in a new clinical trial.